( rrently taking tamoxifen should be swit...)Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen,Health

rrently taking tamoxifen should be switched to anastrozole, to give them the best chance of living cancer-free for longer. In my view women with hormone-receptor positive early breast cancer should be offered the opportunity to receive an aromatase inhibitor like anastrozole immediately after surgery and chemotherapy to provide the best protection against their cancer returning."

Anastrozole cuts recurrence when used as initial adjuvant therapy

These data reinforce the efficacy and tolerability benefits of anastrozole over tamoxifen seen in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) study, which compared 5 years initial adjuvant therapy with anastrozole versus 5 years tamoxifen, and showed that prescribing anastrozole from the start significantly reduces the risk of recurrence. There is a 26% reduction in the risk of recurrence compared with tamoxifen, meaning that 1 in 4 recurrences are prevented by using anastrozole instead of tamoxifen at the start of treatment, when the risk of recurrence is highest.2,3,4,5

Furthermore, data from ATAC show that the majority of the recurrences and also of the serious adverse events associated with tamoxifen occur within the first 2.5 years of treatment, emphasising the importance of using the treatment that is more effective and better tolerated from the outset. Anastrozole remains the only AI to have demonstrated a superior risk:benefit profile compared with tamoxifen over the full 5 year treatment period and beyond, and should establish anastrozole as the emerging gold standard of care for postmenopausal women with early breast cancer. 2

ARNO 95 Trial Design · A prospective, randomised, open-label, parallel group, multi-centre study to assess differences in efficacy and safety between postmenopausal women with hormone receptor?positive breast cancer who switched from tamoxifen (20 or 30mg/d taken for 2 years) to ?Arimidex? (1mg/d taken for up to an additional 3 years), and those w
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
2. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
3. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
4. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
5. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
6. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
7. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
8. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
9. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
10. Once Daily, Extended-Release Ropinirole Improves Parkinsons Symptoms in Patients not Optimally Controlled With Levodopa
11. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival